Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovasc...

Source: Cardiovascular Diabetology - February 8, 2024 Category: Cardiology Authors: Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk D éruaz-Luyet, Julie M. Paik and Elisabetta Patorno Tags: Research Source Type: research